Ergomed Award of Share Options

Ergomed plc

16 June 2023

 

 PRESS RELEASE

Ergomed Award of Share Options

Guildford, UK - 16 June 2023: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Incentive Plan) awards were made to Jonathan Curtain (Chief Financial Officer) on 15 June 2023.

Mr Curtain was awarded a total of 28,866 options over the Company's ordinary shares.  The options have an exercise price of 1 pence per share.  Of the total option award to Mr Curtain, 75% will vest three years after the grant date, conditional upon the achievement of total shareholder return of 15% (compounded annual growth rate). The remaining 25% will vest three years after the grant date subject to continued employment.  The option grant comprises annual discretionary LTIP awards for which Mr Curtain is eligible.

The notification below, made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Jonathan Curtain
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Grant of options under the Company's Long Term Incentive Plan
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		1 pence	28,866
e)	Aggregated information - Aggregated volume - Price - Aggregated total	Options over 28,866 ordinary shares at an exercise price of 1 pence per share
f)	Date of the transaction	15 June 2023
g)	Place of the transaction	Outside a trading venue

ENDS

Enquiries:

Ergomed plc                                                                           Tel: [phone]

Dr Miroslav Reljanović (Executive Chairman)      

Jonathan Curtain (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets and

Strategy)

Numis Securities Limited (Nominated Advisor and Joint            Tel: [phone]

Broker)

Freddie Barnfield / Euan Brown/ Jack McLaren  

Peel Hunt Securities Limited    (Joint Broker)                            Tel: [phone]

James Steel / Dr Christopher Golden

Consilium Strategic Communications  - for UK enquiries         Tel: [phone]

Chris Gardner / Matthew Neal                                                     [e-mail]

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.

 

END